A recent study conducted by The Journal of Pediatrics utilizes our plasma separation cards and finds that newborn screening using plasma holds numerous advantages over dried blood spot (DBS) cards.
While DBS cards are the conventional method for neonatal testing, the study found several issues with this approach. The first issue was that blood dried in a non-uniform manner and there was a possibility of contaminants being introduced. Another issue was that inconsistent blood volume made analysis cumbersome and added more variables. Lastly, cells present in whole blood continued to undergo metabolism and respond to clotting factors, otherwise known as the hematocrit effect.
None of these roadblocks existed when our plasma separation cards were used for neonatal testing.
This is because our technology filters out whole blood in order to provide volumetric samples of pure plasma.
As such, many of the targeted assays were more successful on our plasma separation cards versus the industry-established standard of DBS. Our plasma separation cards also require less blood to be collected than many DBS cards, possibly resulting in less pain and/or discomfort for newborns.
The study concludes that feasibility has been established with Telimmune/Noviplex plasma separation cards for dried plasma spot collection and storage, in combination with LC-MS/MS, for the determination of a broad array of analytes within the healthy newborn metabolome.
We encourage you to read the full study here and reach out to us at info@telimmune.com with any technical questions or opportunities in the pediatric and maternal health markets.
More information about the Telimmune Uno and Telimmune Duo cards: Telimmune Plasma Separation Cards (formerly Noviplex).